Stock Financial Ratios


PTI / Proteostasis Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.86
Volume147,100.00
Market Cap ($M)43.07
Enterprise Value ($M)19.15
Book Value ($M)81.46
Book Value / Share4.34
Price / Book0.97
NCAV ($M)82.39
NCAV / Share2.13
Price / NCAV0.91
Income Statement (mra) ($M)
Revenue8.38
EBITDA-37.45
Net Income-37.23
Balance Sheet (mrq) ($M)
Cash & Equivalents23.92
Cash / Share1.28
Assets62.06
Liabilities10.90
Quick Ratio10.31
Current Ratio10.31
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.46
Return on Assets (ROA)-0.60
Return on Equity (ROE)-0.46
Identifiers and Descriptors
CUSIP74373B109
Central Index Key (CIK)1445283
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)25.10
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Assets Current Per Share3.28
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Intangibles Per Share0.00
Goodwill Per Share0.00
Liabilities Per Share0.58
Accumulated Depreciation And Depletion Per Share0.00
Cash And Equivalents Per Share1.28
Additional Paid In Capital Per Share12.83
Property Plant And Equipment Net Per Share0.03
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Inventory Raw Materials Per Share0.00
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Liabilities And Stock Equity Per Share3.31
Accounts Receivable Per Share0.04
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Equity Per Share2.73
Inventory Per Share0.00
Liabilities Current Per Share0.58
Cash Per Share1.28
Assets Other Non Current Per Share0.00
Assets Per Share3.31
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Per Share0.03
Debt Per Share0.00
Retained Earnings Per Share-10.10
Deferred Income Tax Liabilities Per Share0.00

Related News Stories

This Pharma Stock Is Up 111% and Investors Are Wondering What's Next - Bloomberg

2017-10-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (96-0)

Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?

2017-07-21 zacks
We expect Vertex Pharmaceuticals, Inc. (VRTX - Free Report) to beat expectations when it reports its second-quarter 2017 results on Jul 26, after the market closes. (0-1)

ImmunoGen - Reentry Puzzle

2017-06-30 seekingalpha
One of my best moves in recent times was to follow the advice of Hawkinvest at year end 2016 to buy ImmunoGen below $2.00.

BRIEF-Proteostasis Therapeutics reports preliminary data from phase 1 study of pti-428

2017-06-29 reuters
* Proteostasis Therapeutics reports preliminary data from phase 1 study of pti-428 in patients with cystic fibrosis (0-4)

Akcea, A Wholly Owned Subsidiary Of Ionis Pharmaceutical, Set To IPO

2017-06-27 seekingalpha
Akcea Therapeutics, a wholly-owned subsidiary of Ionis Pharmaceutical, is expected to IPO on Friday, June 30. (0-1)

CUSIP: 74373B109